HenryCPitotMD

PubMed

• 5881 citations
  Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
  Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian
  The New England Journal of Medicine. 2012-06-28
• 1264 citations
  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
  Amy R. Moser, Henry C. Pitot, William F. Dove
  Science. 1990-01-19
• 401 citations
  Pathology of mouse models of intestinal cancer: Consensus report and recommendations
  Gregory P. Boivin, Kay Washington, Kan Yang, Jerrold M. Ward, Theresa P. Pretlow
  Gastroenterology. 2003-03-01

Journal Articles

• Phase 2 study of bevicizumab plus erlotinib in patients with advanced hepatocellular cancer  
  Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C, Cancer, 1/1/2011
• Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial  
  Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J, Int J Gastrointest Cancer, 1/3/2008
• The Phan/Yao article reviewed--Small steps forward in the land of small tumors  
  Hobday TJ, Pitot HC, Oncology, 1/1/2008
• Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors  
  Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C, J Clin Oncol, 1/1/2002
• Future directions in adjuvant therapy for stage III colon carcinoma  
  Pitot HC, Goldberg RM, Oncology, 1/1/2001
• An NCCTG Phase II Trial of 9-Amino Camptothecin in Previously Untreated Patients With Measurable Metastatic Colorectal Cancer  
  Pitot H, Knost J, Mahoney M, Kugler J, Krook J, Hatfield A, Goldberg R, Sargent D, Cancer, 1/1/2000
• The Damjanov/Meropol article reviewed  
  Pitot HC, Goldberg RM, Oncology, 1/1/2000
• Treatment of advanced colorectal carcinoma  
  Pitot HC, Mayo Clinical Update, 1/1/1997
• Join now to see all

Books/Book Chapters

• Mayo Internal Medicine Board Review 2002-03 
  Chapter: Chapter 19: Oncology 
  Okuno SH, Pitot HCEditors: Thomas M, Habermann MD.Lippincott Williams & Wilkins2002
• Mayo Internal Medicine Board Review 2000-01 
  Chapter: Chapter 18: Oncology 
  Okuno SH, Pitot HCEditors: Udaya BS, Prakash MD.Lippincott Williams & Wilkins2000
• Cancer Chemotherapy and Biological Response Modifiers/13 
  Chapter: Breast Cancer 
  Pitot H, Loprinzi CLEditors: Pinedo HM, et al..Elsevier Science Publishers, Amsterdam1992

Lectures

• Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advance... 
  Chicago, IL - 1/1/2016
• Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P) 
  Chicago, IL - 1/1/2016
• The association of JAK2 polymorphisms with prognosis in castration-resistant prostate cancer (CRPC) 
  San Francisco, CA - 1/1/2016
• Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P) 
  San Francisco, CA - 1/1/2016
• Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors 
  Chicago, IL - 1/1/2015
• First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results 
  Chicago, IL - 1/1/2014
• Association of germ-line genetic variation with failure of androgen ablation (AA) in hormone-sensitive advanced prostate cancer 
  Chicago, IL - 1/1/2013
• A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study 
  Chicago, IL - 1/1/2013
• Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC) 
  Orlando, FL - 1/1/2013
• PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors 
  Chicago, IL - 1/1/2012
• Different Treatment Options for Metastatic Urothelial Carcinoma 
  Santiago, Chile - 1/12/2011
• Neoadjuvant and Adjuvant Treatment of Bladder Cancer 
  Santiago, Chile - 1/12/2011
• The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 
  Chicago, IL - 1/1/2011
• MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer 
  Orlando, FL - 1/1/2011
• Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma 
  Orlando, FL - 1/1/2011
• Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449 
  Orlando, FL - 1/1/2011
• Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841 
  Chicago, IL - 1/1/2011
• Anti-B7-H1 Clinical Trial 
  Rochester, MN - 1/26/2010
• Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients 
  Orlando, FL - 1/1/2009
• Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors 
  Orlando, FL - 1/1/2009
• Liver Cancer 
  Rochester, MN - 1/1/2008
• Management of Prostate Cancer 
  Kauai, HI - 1/1/2006
• Symptom Management in Cancer Patients 
  Kauai, HI - 1/1/2006
• N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Paitents with Advanced Colorectal Carcinoma Previously Treated with 5-Fluorour... 
  Orlando, FL - 1/1/2005
• The IRB and Its Role in Protecting Human Subjects 
  Rochester, MN, 2003 - 1/1/2004
• Join now to see all